illumiSonics and Sunnybrook Launch INOVAIT Focus Fund–Backed Clinical Trial Bringing Label-Free Laser Histology to Mohs Skin Cancer Surgery illumiSonics Inc., a medical technology company commercializing label-free tissue imaging, announced the launch of a prospective clinical validation study at Sunnybrook Health…
Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older Almirall, S.A. a global biopharmaceutical company focused on medical dermatology, today announced that the European Medicines Agency (EMA) has…
IQVIA’s Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare…
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) announced a partnership to expand access to high-quality human induced…
HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001 Immunomic Therapeutics Inc., a clinical-stage biotechnology company and a subsidiary of HLB, announced that the first participant has been dosed in the Phase…
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule…
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies Antares Therapeutics, Inc. a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop…
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Definium Therapeutics, Inc. a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes…
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Pfizer Inc. announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential…
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch…
Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. to accelerate AI-enabled drug discovery using Greenstone’s large-scale, human biobank of induced pluripotent stem cells and Intel’s Edge AI advanced computing and AI infrastructure. Intel and Greenstone are working together…
101 Therapeutics Releases Clinical Evidence Package for Macrophage-Targeted 101-PGC-005 and Seeks Urgent Independent Review for Bundibugyo Ebola Disease 101 Therapeutics Ltd. today announced the public release of its clinical and scientific evidence package for 101-PGC-005 (‘005), a macrophage-targeted dexamethasone prodrug…